The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics.
Cancer
Circadian
Clock gene
Glucocorticoid
Immune checkpoint inhibitor
Immuno-oncology
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
23
12
2020
accepted:
18
03
2021
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
16
11
2021
Statut:
epublish
Résumé
The circadian system temporally regulates physiology to maintain homeostasis. Co-opting and disrupting circadian signals appear to be distinct attributes that are functionally important for the development of a tumor and can enable or give rise to the hallmarks that tumors use to facilitate their initiation, growth and progression. Because circadian signals are also strong regulators of immune cell proliferation, trafficking and exhaustion states, they play a role in how tumors respond to immune-based cancer therapeutics. While immuno-oncology has heralded a paradigm shift in cancer therapeutics, greater accuracy is needed to increase our capability of predicting who will respond favorably to, or who is likely to experience the troubling adverse effects of, immunotherapy. Insights into circadian signals may further refine our understanding of biological determinants of response and help answer the fundamental question of whether certain perturbations in circadian signals interfere with the activity of immune checkpoint inhibitors. Here we review the body of literature highlighting circadian disruption as a cancer promoter and synthesize the burgeoning evidence suggesting circadian signals play a role in how tumors respond to immune-based anti-cancer therapeutics. The goal is to develop a framework to advance our understanding of the relationships between circadian markers, cancer biology, and immunotherapeutics. Bolstered by this new understanding, these relationships may then be pursued in future clinical studies to improve our ability to predict which patients will respond favorably to, and avoid the adverse effects of, traditional and immune-based cancer therapeutics.
Identifiants
pubmed: 33794967
doi: 10.1186/s13046-021-01919-5
pii: 10.1186/s13046-021-01919-5
pmc: PMC8017624
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Références
Cell. 2016 Apr 7;165(2):303-16
pubmed: 27058663
Cancer Med. 2019 Apr;8(4):1710-1720
pubmed: 30791227
Trends Cancer. 2019 Aug;5(8):475-494
pubmed: 31421905
J Biol Chem. 2012 Nov 9;287(46):39107-14
pubmed: 22992773
Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15-e21
pubmed: 28877075
Int J Mol Sci. 2020 Mar 07;21(5):
pubmed: 32156004
BMC Cancer. 2016 Apr 21;16:285
pubmed: 27102330
BMC Biol. 2017 Feb 14;15(1):13
pubmed: 28196531
Cancers (Basel). 2020 Apr 01;12(4):
pubmed: 32244760
J Mol Cell Cardiol. 2009 Apr;46(4):545-52
pubmed: 19168071
Aging (Albany NY). 2019 Dec 23;11(24):11814-11828
pubmed: 31881010
Cancer Causes Control. 2006 May;17(4):525-30
pubmed: 16596306
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12662-7
pubmed: 22778400
J Med Chem. 2018 Jul 26;61(14):5794-5804
pubmed: 29412659
PLoS One. 2013;8(4):e61142
pubmed: 23577201
Front Oncol. 2018 Jun 12;8:185
pubmed: 29946530
Immunity. 2012 Feb 24;36(2):251-61
pubmed: 22342842
Nat Commun. 2018 Dec 18;9(1):5372
pubmed: 30560953
Cell Cycle. 2011 Dec 1;10(23):4162-9
pubmed: 22101268
Oncol Rep. 2017 Jul;38(1):472-480
pubmed: 28535015
J Cancer Res Clin Oncol. 2012 Mar;138(3):501-11
pubmed: 22198637
Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R271-7
pubmed: 16987893
BMC Cancer. 2010 Mar 24;10:110
pubmed: 20334671
Nat Commun. 2020 Jun 24;11(1):3193
pubmed: 32581213
Biomed Res Int. 2020 Feb 22;2020:8587458
pubmed: 32185221
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
JCI Insight. 2017 Sep 21;2(18):
pubmed: 28931759
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
PLoS One. 2019 Jan 10;14(1):e0202458
pubmed: 30629581
Nat Commun. 2017 Sep 12;8(1):417
pubmed: 28900189
Front Immunol. 2019 Oct 24;10:2451
pubmed: 31708917
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Nature. 2018 Jan 18;553(7688):351-355
pubmed: 29320480
Curr Top Med Chem. 2002 Feb;2(2):113-32
pubmed: 11899096
Br J Cancer. 2017 Jun 6;116(12):1558-1563
pubmed: 28524161
Oncotarget. 2016 Dec 27;7(52):85832-85847
pubmed: 27494874
Pathol Oncol Res. 2010 Sep;16(3):403-11
pubmed: 19957060
Mol Cancer Res. 2010 Jul;8(7):952-60
pubmed: 20551151
Psychoneuroendocrinology. 2015 Mar;53:256-67
pubmed: 25647344
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21609-21617
pubmed: 32817420
Nat Med. 2018 Dec;24(12):1795-1803
pubmed: 30523327
Clin Exp Metastasis. 2020 Oct;37(5):617-635
pubmed: 32816185
PLoS One. 2012;7(8):e42324
pubmed: 22870317
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Psychoneuroendocrinology. 2010 Aug;35(7):963-76
pubmed: 20097011
Cancer Causes Control. 2006 May;17(4):509-14
pubmed: 16596304
Cell. 2015 Sep 10;162(6):1338-52
pubmed: 26359987
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):582-7
pubmed: 22184247
Sleep. 2003 May 1;26(3):342-92
pubmed: 12749557
Cell Syst. 2018 Mar 28;6(3):314-328.e2
pubmed: 29525205
Oncogenesis. 2018 Oct 8;7(10):79
pubmed: 30293994
PLoS Biol. 2019 Apr 30;17(4):e3000228
pubmed: 31039152
J Neurooncol. 2014 May;118(1):109-16
pubmed: 24532241
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Cancer. 2018 Sep 15;124(18):3706-3714
pubmed: 29975414
Curr Opin Cell Biol. 2020 Dec;67:17-26
pubmed: 32771864
Trends Cell Biol. 2018 May;28(5):368-379
pubmed: 29471986
Immunity. 2008 Jan;28(1):29-39
pubmed: 18164222
Nucleic Acids Res. 2014 Jul;42(12):7694-707
pubmed: 24914052
Biochem Pharmacol. 2015 Aug 15;96(4):315-22
pubmed: 26074263
Nat Rev Immunol. 2018 Jul;18(7):423-437
pubmed: 29662121
Mol Cell. 2016 Nov 17;64(4):774-789
pubmed: 27840026
Clin Cancer Res. 2006 May 15;12(10):3003-9
pubmed: 16707595
J Cancer. 2018 Jun 14;9(14):2480-2491
pubmed: 30026846
Int J Mol Sci. 2019 Sep 12;20(18):
pubmed: 31547330
Nat Commun. 2014 Oct 03;5:5073
pubmed: 25278152
J Immunother. 2005 Nov-Dec;28(6):517-24
pubmed: 16224268
Science. 2009 May 1;324(5927):654-7
pubmed: 19286518
Psychooncology. 2018 Oct;27(10):2500-2507
pubmed: 30117225
Nutr Rev. 2012 Aug;70(8):459-71
pubmed: 22835139
PLoS One. 2013 Apr 23;8(4):e61679
pubmed: 23626715
Genome Med. 2019 Dec 17;11(1):82
pubmed: 31847894
Toxicol Lett. 2018 Oct 1;295:314-324
pubmed: 29981919
Mol Med Rep. 2016 Jun;13(6):4561-8
pubmed: 27082164
Oncol Rep. 2016 Jun;35(6):3387-94
pubmed: 27035749
Physiol Behav. 2008 Nov 28;95(4):570-80
pubmed: 18761026
Ann Med. 2014 Jun;46(4):191-207
pubmed: 24915535
Science. 2013 Nov 8;342(6159):727-30
pubmed: 24202171
Mamm Genome. 2017 Feb;28(1-2):1-12
pubmed: 27671790
Cancer Discov. 2018 Oct;8(10):1250-1257
pubmed: 30154193
Science. 2015 Jun 26;348(6242):1488-92
pubmed: 26044300
Support Care Cancer. 2014 Apr;22(4):1121-30
pubmed: 24389829
Comp Med. 2018 Aug 1;68(4):269-279
pubmed: 29875029
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32295075
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Clin Cancer Res. 2000 Aug;6(8):3038-45
pubmed: 10955782
Nucleic Acids Res. 2016 May 5;44(8):e80
pubmed: 26819407
Clin Cancer Res. 2019 Jun 15;25(12):3508-3516
pubmed: 30819679
Proc Natl Acad Sci U S A. 2017 May 16;114(20):5312-5317
pubmed: 28439010
Chronobiol Int. 2014 Feb;31(1):37-51
pubmed: 24164100
J Biol Rhythms. 2005 Oct;20(5):391-403
pubmed: 16267379
J Cell Signal. 2020;1(3):42-49
pubmed: 32728672
Cancer Med. 2018 Sep;7(9):4396-4405
pubmed: 30088335
Nat Med. 2019 Sep;25(9):1428-1441
pubmed: 31501614
Cancer Lett. 2019 Sep 10;459:59-71
pubmed: 31132432
Oncoimmunology. 2012 Jul 1;1(4):529-530
pubmed: 22754774
Trends Pharmacol Sci. 2018 Sep;39(9):812-827
pubmed: 30060890
Nature. 2019 Mar;567(7749):540-544
pubmed: 30867597
J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000
pubmed: 10861311
Annu Rev Pharmacol Toxicol. 2007;47:593-628
pubmed: 17209800
Cell. 2007 May 4;129(3):461-4
pubmed: 17482541
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Genome Med. 2020 Aug 21;12(1):73
pubmed: 32825850
Chronobiol Int. 2011 Dec;28(10):841-51
pubmed: 22080729
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122
Cancer Res. 2009 Jun 1;69(11):4700-7
pubmed: 19470769
J Pineal Res. 2000 Oct;29(3):129-37
pubmed: 11034109
Nucl Recept Signal. 2009;7:e003
pubmed: 19381306
Brain Behav Immun. 2013 Mar;30 Suppl:S163-70
pubmed: 22884416
Cancer Cell. 2020 Apr 13;37(4):599-617.e7
pubmed: 32243837
PLoS One. 2013;8(2):e57921
pubmed: 23469106
Science. 2003 Oct 10;302(5643):255-9
pubmed: 12934012